Intellia Therapeutics (NASDAQ: NTLA) shares are soaring 5.07% in pre-market trading on Friday, following bullish analyst reports that reaffirm confidence in the gene-editing company's potential.
The stock's upward movement comes on the heels of two major Wall Street firms maintaining their positive outlook on Intellia. Chardan Capital reiterated its Buy rating on the company, signaling continued optimism about Intellia's prospects in the competitive gene therapy landscape. This vote of confidence was echoed by Bank of America Securities analyst Alec Stranahan, who also reaffirmed a Buy rating on Intellia Therapeutics in a report released Thursday.
These positive analyst sentiments appear to be driving investor enthusiasm, pushing the stock higher before the market opens. The maintained Buy ratings suggest that despite the challenges inherent in the biotech sector, analysts believe Intellia's innovative CRISPR-based therapies and robust pipeline continue to position the company favorably for future growth. As the market digests this information, investors will be watching closely to see if this pre-market surge translates into sustained gains throughout the trading day.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。